MedTrace Logo

Evaluation of Brain Atrophy in CIS Patients on Avonex

NCT01592474 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2014-07-09

No results posted yet for this study

Summary

The purpose of this study is

* To examine if Avaonex can delay the development of clinically definite multiple sclerosis.
* To investigate if Avonex can delay disability progression by slowing brain atrophy.

Conditions

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Jacobs Neurological Institute

    collaborator OTHER

  • Charles University, Czech Republic

    collaborator OTHER

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Robert Zivadinov, MD,PhD,FAAN · University at Buffalo

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2011-08-31
Completion
2012-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01592474 on ClinicalTrials.gov